Skip to main content
. Author manuscript; available in PMC: 2019 Sep 30.
Published in final edited form as: Eur J Pharmacol. 2019 Jan 25;848:131–139. doi: 10.1016/j.ejphar.2019.01.037

Fig. 6.

Fig. 6.

Neither 5-HT2C receptor inverse agonist efficacy nor potency at the IP pathway correlates with 5-HT2C receptor sensitization of the IP pathway. A. IP reduction, Imax (decrease from basal); B. IP production, pIC50.